**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a case series involving five rheumatic disease patients, who were admitted with COVID-19 between 16 January 2020 and 28 March 2020, a 66-year-old woman and 79-year-old man were described, of whom the woman developed COVID-19 infection during treatment with methotrexate and infliximab for rheumatoid arthritis, and the man developed COVID-19 infection during treatment with methylprednisolone for systemic sclerosis \[*routes not stated*\].

A 66-year-old woman, who had a history of rheumatoid arthritis and hypertension, presented to a hospital with fever and cough. She had been receiving methotrexate 10 mg/week and infliximab 200 mg once every 2 months, for 2 years. She stopped receiving infliximab before admission to the hospital. Laboratory findings revealed WBC count 3.08 × 10^9^/L, neutrophil count 1.65 × 10^9^/L, lymphocyte count 1.11 × 10^9^/L, and a chest CT scan showed patchy ground glass opacity. She also tested positive for SARS-CoV-2 test. Therefore, she was diagnosed with mild COVID-19 infection. She also had contact history with confirmed COVID-19 patients. Thus, she was admitted and started receiving off-label ribavirin and umifenovir \[Arbidol\]. She also received unspecified antibacterial therapy. Subsequently, she was found to be negative for SARS-CoV-2 nucleic acid test, and was discharged after 16 days of hospitalisation. It was reported that the immunosuppressant effect of infliximab and methotrexate had attributed to the COVID-19 infection.

A 79-year-old man, who had a history of systemic sclerosis and chronic obstructive pulmonary disease, presented to a hospital with fever, cough and dyspnoea. He had been receiving methylprednisolone 8 mg/day for 1 year. He was tested positive for SARS-CoV-2 test. Laboratory findings were as follows; WBC count 5.16 × 10^9^/L, neutrophil count 4.86 × 10^9^/L, lymphocyte count 0.19 × 10^9^/L along with elevated levels of CRP, IL-6 and IL-10. A chest CT scan revealed grid shadow, which was suggestive of interstitial pneumonia. Based on the findings, he was diagnosed with critical COVID-19. However, he had no contact history with confirmed COVID-19 patients. He was admitted and started receiving off-label ribavirin, interferon-gamma and umifenovir \[Arbidol\]. He also received noninvasive ventilator treatment and high-flow oxygen inhalation along with unspecified antibacterial therapy, methylprednisolone 40 mg/day for 5 days and IV immune globulin. The methylprednisolone treatment was continued during the entire period of hospitalisation. Subsequently, he was found to be negative for SARS-CoV-2 nucleic acid test, and was discharged after 31 days of hospitalisation. It was reported that his underlying disease and methylprednisolone treatment attributed to the COVID-19 infection.
